Thu, Aug 21, 2014, 9:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Nov 6, 2013 2:30 PM Flag

    RET fusion gene: Translation to personalized lung cancer therapy

    $$$$
    Published at the Wiley On-line Library...10/1/13, titled as above.
    Good comparative data source for current trials in RET fusion NSCLC.
    Cabo, Vandetanib, Lenvatenib, Ponatinib...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sales of Vandetanib were pretty strong according to a survey of analysts' estimates:

      $5 million in 2011
      $31 million in 2012
      Forecast:
      $58 million in 2013
      $95 million in 2014
      $134 million in 2015

      This despite the REMS and anticipated competition from Cabo which looks superior in many ways. Vandetanib's acceptance in NSCLC seems tenuous as they withdrew their bid for approval in the EU, and weren't mentioned in the NCCN for Ret fusion NSCLC. Cabo by comparison has the following estimates:

      Forecast:
      $16 million in 2013
      $36 million in 2014
      $59 million in 2015

      Seems low when you compare the capabilities and drawbacks of these drugs. We're clearly not under intense scrutiny just yet.

    • Here's some more reading material. "Cleveland Clinic Using Foundation Medicine Test for Study on Impact of Sequencing in Cancer Care" This study is relevant for 2 reasons. It may hit on a few NSCLC RET fusion patients and it may also turn up other as yet unidentified cancers driven by RET mutations

 
EXEL
4.09-0.02(-0.49%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.